Journal of Neurology

, Volume 234, Issue 2, pp 94–96

Depression and parkinson's disease: possible role of serotonergic mechanisms

  • V. S. Kostić
  • B. M. Djuričić
  • N. Čovičković-Šternić
  • L. Bumbaširević
  • M. Nikolić
  • B. B. Mršulja
Original Investigations

Summary

Depression is frequently encountered in Parkinson's disease and was seen to occur in 14 of 26 patients studied. The levels of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin (5-HT), in CSF samples of the patients were significantly lower than in those of controls. However, within the group of patients the levels of 5-HIAA in CSF samples were significantly lower in the depressive subgroup compared with the non-depressive patients. Moreover, no correlation was recorded between motor disability and depression. The results indicate that disturbed 5-HT metabolism may possibly play a role in Parkinson's disease as a predisposing factor in the development of depression.

Key words

Parkinson's disease Depression Human cerebrospinal fluid 5-Hydroxyindoleacetic acid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Asberg M, Thoren P, Traskman L, Bertlsson I, Ringberger V (1976) “Serotonin depression” — a biochemical subgroup within the affective disorders. Science 191:478–480Google Scholar
  2. 2.
    Barbeau AL (1969) l-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 101:791–800Google Scholar
  3. 3.
    Celesia GG, Wanamaker WM (1972) Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst 33:577–583Google Scholar
  4. 4.
    Fibiger HC (1984) The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 11:105–107Google Scholar
  5. 5.
    Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62Google Scholar
  6. 6.
    Horn S (1974) Some psychological factors in parkinsonism. J Neurol Neurosurg Psychiatry 37:27–31Google Scholar
  7. 7.
    Laverty R, Taylor KM (1968) The fluorimetric assay of catecholamines and related compounds: improvements and extension to the hydroxyindole technique. Anal Biochem 22:269–279Google Scholar
  8. 8.
    Markham CH, Diamond SG (1981) Evidence to support early therapy in Parkinson disease. Neurology 31:125–131Google Scholar
  9. 9.
    Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment and Parkinson disease. Neurology 31:645–650Google Scholar
  10. 10.
    Mayeux R, Yaakov S, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34:642–646Google Scholar
  11. 11.
    Mindham RHS, Marsden CD, Parkes JD (1976) Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol Med 6:23–33Google Scholar
  12. 12.
    Parkinson J (1938) An essay of the shaking palsy, 1817. Med Classics 2:964–997Google Scholar
  13. 13.
    Riederer P, Birkmayer W, Seemann D, Wuketich S (1977) Brain noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease. J Neural Transm 41:241–251Google Scholar
  14. 14.
    Robins AH (1976) Depression in patients with parkinsonism. Br J Psychiatry 128:141–145Google Scholar
  15. 15.
    Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid I (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321–328Google Scholar
  16. 16.
    Sourkes TL (1976) Parkinson's disease and other disorders of the basal ganglia. In: Sigel GJ, Albers RW, Katzman R, Agranoff BW (eds) Basic neurochemistry. Little, Brown and Co., Boston, pp 668–684Google Scholar
  17. 17.
    Van Prag HM (1982) Serotonin precursors in the treatment of depression. In: Ho BT, Schooler JC, Usdin E (eds) Serotonin in biological psychiatry. Raven Press, New York, pp 259–286Google Scholar
  18. 18.
    Yahr MD, Davidsin RS, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21:343–354Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • V. S. Kostić
    • 1
  • B. M. Djuričić
    • 2
  • N. Čovičković-Šternić
    • 1
  • L. Bumbaširević
    • 1
  • M. Nikolić
    • 1
  • B. B. Mršulja
    • 2
  1. 1.Department of NeurologySchool of MedicineBelgradeYugoslavia
  2. 2.Institute of BiochemistrySchool of MedicineBelgradeYugoslavia

Personalised recommendations